anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a retrospective and prospective, multicenter observational quality improvement study and research registry. Infants undergoing renal replacement therapy utilizing CARPEDIEM for hemodialysis will be enrolled in the study for observation. There are two arms to this study, one for quality improvement and one for research purposes. Patients enrolled in this study have the option to participate additionally in either biospecimen collection, long term follow up after CARPEDIEM, or both. Urine specimen will be collected from fresh voids, but all blood specimen will be obtained from residual clinical specimen. Investigators hope to gain more information into use, treatment course, and outcomes from infants requiring treatment with the CARPEDIEM device.
A granulate, possibly pressed into the form of tablets, contains at least one insoluble, complex bound or barely soluble material in powder form, which can bind or neutralize acids, and which does not react with the acid of the effervescent system, and an effervescent system, consisting of at least one organic, edible acid and at least one alkaline or alkaline earth carbonate and/or bicarbonate. The active material is present in a quantity of 5 to 50 %, preferably 8 to 30 %, and in particular 12 to 25 % by weight. It has an acid binding power of between 2 and 40, preferably 3.5 to 25 mEq/g, does not react with the acid of the effervescent system and raises the pH value in 0.1 n HCl during 2 min. by a maximum of 0.5. It consists in particular of magnesium trisilicate, sucralfate and/or a bismuth salt. Each granule contains at least one acid component, at least one carbonate component and at least one active material bound to one another. The binding of the granulate components together is effected by a reaction product from an acid with a carbonate component and/or by at least one hydrocolloid, in particular xanthane, maltodextrin, galactomanane and/or tragacanth.
The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
Silver-coated proteins, being dissolvable or suspendable in aqueous media and/or retaining a biological activity of the protein and a process for preparing same are disclosed. Further disclosed are modified proteins which have a reducing moiety attached to the surface thereof and a process for preparing same. The modified proteins can be utilized for obtaining the silver-coated proteins. Further disclosed are a pharmaceutical composition containing and a method of treating bacterial and fungal infections utilizing biologically active silver-coated hydrogen peroxide producing enzymes such as glucose oxidase. Further disclosed are conductive elements that comprise the silver-coated proteins disclosed herein and electronic circuits containing same. Further disclosed are electrodes having the silver-coated proteins deposited thereon and biosensor systems utilizing same for determining a level of an analyte in a liquid sample.
Patients with locally advanced or metastatic breast cancer that has failed or is intolerant to standard of care therapies. Includes, HER2+, HER 2-, TNBC.
The present invention relates to a coated Stachys japonica Miq. on which functional coating solutions such as a cacao coating solution, a blueberry coating solution, and a Schisandra chinensis (Turcz.) Baill. coating solution are applied to freeze-dried Stachys japonica Miq. The present invention further relates to a production method thereof. The coated Stachys japonica Miq. of the present invention minimizes a loss of nutrition and biological activity of Stachys japonica Miq. such as improvement in memory and prevention of cerebral infarction and dementia, and also can reduce side effects such as diarrhea. In addition, the coated Stachys japonica Miq. also ensures excellent storability and functionality such as excellent external appearance, texture, and anyone can easily intake the coated Stachys japonica Miq. while carrying the same, since the coating solutions are barely stuck on hands.
Approved therapies for hepatitis B virus (HBV) treatment include nucleos(t)ides and interferon alpha (IFN-α) which effectively suppress viral replication, but they rarely lead to cure. Expression of viral proteins, especially surface antigen of the hepatitis B virus (HBsAg) from covalently closed circular DNA (cccDNA) and the integrated genome, is believed to contribute to the persistence of HBV. This work focuses on therapies that target the expression of HBV proteins, in particular HBsAg, which differs from current treatments. Here we describe the identification of AB-452, a dihydroquinolizinone (DHQ) analogue. AB-452 is a potent HBV RNA destabilizer by inhibiting PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model. AB-452 showed acceptable tolerability in 28-day rat and dog toxicity studies, and a high degree of oral exposure in multiple species. Based on its in vitro and in vivo profiles, AB-452 was identified as a clinical development candidate.
No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
PURPOSE:To provide an immunopotentiative agent using the fraction collected by extracting the cultured mycelia or fruits of Hericium coralloides (Fr.) S.F. Gray with hot water and using the extract or a high-molecular-weight precipitate therefrom with alcohol, as an active ingredient. CONSTITUTION:This immunopotentiative agent comprises an extract from the cultured mycelia of Hericium coralloides (Fr.) with hot water or a high- molecular-weight fraction (a concentrate of the active substance) collected from the hot water extract by precipitation or its concentrate with a water-soluble solvent such as an alcohol. The fraction is obtained by adding 0.5 to 5 pts.wt. of a lower alcohol such as ethanol, methanol or propanol to 1 pt.wt. of the hot-water extract from the cultured mycelia or the concentrate thereof. Particularly, the hot-water extract from the fruits or its concentrate is preferred.
The invention discloses an anti-CD 16A nano antibody and application thereof, wherein a heavy chain variable region of the nano antibody comprises a CDR1, a CDR2 and a CDR3, wherein the amino acid sequence of the CDR1 is shown as SEQ ID NO. 1, the amino acid sequence of the CDR2 is shown as SEQ ID NO. 2, and the amino acid sequence of the CDR3 is shown as SEQ ID NO. 3. The anti-CD 16A nanobody can specifically bind to a CD16A antigen, the affinity of the nanobody is 10  ‑9  M, and the anti-CD 16A nanobody belongs to a high-affinity nanobody. The hetero-dimeric bispecific antibody constructed by the anti-CD 16A nano-antibody and the anti-CD 22 nano-antibody still keeps good antigen binding activity on CD16A, has stronger killing activity on acute B lymphocyte leukemia, effectively improves the treatment effect, and can provide a novel method for high-efficiency and lasting anti-tumor.
Compsns. with pharmaceutical and/or antimicrobial activity contain glucaric acid (I), a salt, ester and/or amide of (I), and/or glucarolactone. The compsns. can be used as antibacterial and antifungal medicaments, industrial microbicides, food preservatives, agricultural fungicides and disinfectants. They are also beta-glucuronidase inhibitors, e.g. for potentiating the effect of antibiotics. They are also stated to promote the growth of hair and nails. They can be used to replace cortisone in bronchial asthma therapy, to treat disorders of the mucous membranes and arteries (e.g. as nasal decongestants and for treatment of haemorrhoids), to protect against viral infections, and to treat insect bites. They are also useful no geriatric medicaments, hypolipaemic agents, antiperspirants and deodorants.
Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
The technical field of the invention relates to: (1) certain photosensitive substances used with lasers for discovery and destruction of tumors; (2) methods of making the substances; (3) use of the substances; and (4) certain light-delivery equipment used with the substance. To obtain tumor-selective, photosensitizing substances useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. Other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophilic. The substance is injected into the patient, clears normal tissue and then neoplastic tissue is irradiated using lasers. Laser equipment includes a light conductor and transmitting head with light differing surface and feedback path for radiated light related to dosage.
Child/parent dyads will be randomized to one of two intervention conditions: (1) Parent-child model, also known as the Caregiver Education Model (CMM):focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves individual interventionist meetings with the parents and their children in their homes for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child. (2)Parent-education intervention, also known as the Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton \& Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton \& Tonge 2005). In the CEM condition, parents meet in a group, without their children, in a community-based setting to receive the intervention. Intervention in both conditions occurs for 2 hours for 12 weeks.
Trial 03 was a randomized, double-blind, placebo-controlled multicenter trial for the prevention of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection (MA RSV LRTI) conducted in preterm infants born at gestational age (GA) greater than or equal to 29 weeks and less than 35 weeks. These subjects were randomized 2:1 to receive BEYFORTUS (N=969) or placebo (N=484) by IM injection. All subjects in the BEYFORTUS arm received 50 mg IM of BEYFORTUS regardless of body weight. The recommended BEYFORTUS dose in neonates and infants born during or entering their first RSV season is a single IM 50 mg or 100 mg dose for those who weigh less than 5 kg and greater than or equal to 5 kg, respectively [see Dosage and Administration (2.1)].

At randomization, 20% were GA greater than or equal to 29 weeks and less than 32 weeks; 80% were GA greater than or equal to 32 and less than 35 weeks; 52% were male; 72% were White; 18% were Black; 1% were Asian; 1% were Pacific Islander, and 8% were Other or Mixed Race; 22% were Hispanic or Latino; 68% were from Northern Hemisphere. The median age was 2.8 months (range: 0.1 to 11.9 months); 53% were less than or equal to 3 months; 33% were greater than 3 to less than or equal to 6 months, and 14% were greater than 6 months of age.

The primary endpoint was the incidence of MA RSV LRTI caused by RT-PCR-confirmed RSV, characterized predominantly as bronchiolitis or pneumonia through 150 days after dosing. Medically Attended (MA) includes all healthcare provider visits such as physician office, urgent care, emergency room visits and hospitalizations. Signs of LRTI involvement included rhonchi, rales, crackles, or wheezing; and at least one sign of worsening clinical severity including at least one of the following: increased respiratory rate, hypoxemia, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, retractions, grunting, or dehydration due to respiratory distress. Incidence of RSV LRTI with hospitalization was a prespecified secondary endpoint. RSV hospitalization was defined as hospitalization for LRTI with a positive RSV test.

Table 5 displays the primary efficacy result for Trial 03.

In Trial 03, the efficacy of BEYFORTUS against MA RSV LRTI with hospitalization in infants born at GA greater than or equal to 29 weeks and less than 35 weeks, who received a single dose of 50 mg BEYFORTUS, based on the relative risk reduction was 78.4% (95% CI 51.9, 90.3; p=0.0002), through 150 days post dose.
Consecutive adult patients (≥18 years of age) presenting acutely (i.e. unplanned and non-elective presentation to hospital for urgent or emergency reasons) for symptoms of known or unknown colorectal cancer assessed by hospital surgical teams. Patients should be included regardless of operative or non-operative management, and curative or palliative intent.
BACKGROUND: Chronic low back pain (LBP) is a leading cause of disability, which is exacerbated in some by repeated lifting. Electromyography (EMG) assessments of isolated erector spinae (ES) regions during lifting identified conflicting results. Here, high-density EMG comprehensively assesses the lumbar and thoracolumbar ES activity in people with and without LBP performing a multiplanar lifting task.
METHODS: Four high-density EMG grids (two bilaterally) and reflective markers were affixed over the ES and trunk to record muscle activity and trunk kinematics respectively. The task involved cyclical lifting of a 5 kg box for ∼7 min from a central shelf to five peripheral shelves, returning to the first between movements, while monitoring perceived exertion.
RESULTS: Fourteen LBP (26.9 ± 11.1 years) and 15 control participants (32.1 ± 14.6 years) completed the study. LBP participants used a strategy characterised by less diffuse and more cranially-focussed ES activity (P < 0.05). LBP participants also exhibited less variation in ES activity distribution between sides during movements distal to the central shelf (P < 0.05). There were few consistent differences in kinematics, but LBP participants reported greater exertion (P < 0.05).
CONCLUSION: In the presence of mild LBP, participants used a less variable motor strategy, with less diffuse and more cranially-focussed ES activity; this motor strategy occurred concomitantly with increased exertion while completing this dynamic task.
The invention discloses a Chinese herb medicine used for bronchial asthma and a taking method of the Chinese herb medicine used for the bronchial asthma. The Chinese herb medicine comprises a main medicine and a guiding medicine. The main medicine is composed of kelp bases, giant typhonium rhizomes, cynanchum stauntoni, unibract fritillary bulbs, peucedanum praeruptorum, rhizome arisaematis, tussilago farfara, aster tataricus, Chinese waxgourd seeds, Chinese cabbage roots and seal clam shell powder. The guiding medicine is composed of eriobotrya japonica Thunb, seaweeds, pulvis fellis suis, mulberry barks, bamboo leaves and ginkgo leaves. The multiple kinds of traditional Chinese medicinal materials which have the effects of relieving a cough and relieving asthma are selected and used for medicine compatibility, the appropriate guiding medicine is selected and used for conditioning and effect improving on the medicine effect, and therefore the treatment effect on the bronchial asthma by the medicine is greatly improved, and the bronchial asthma does not relapse. The selected medicinal materials for use are common and cheap, the decoction and taking methods are simple, and the Chinese herb medicine is widely suitable for kinds of crowds. The clinical experimental result shows that the curing effect on the bronchial asthma reaches over 93%, and the Chinese herb medicine has no side effect, does not generate medicine dependence and is well received by patients.
<P>PROBLEM TO BE SOLVED: To provide an agent for increasing thickness of hair, capable of not only improving an appearance of the hair, but also achieving increase in volume of the hair by substantially thickening the hair one by one and increasing weight of the hair, for the purpose of improving sparse hair, and capable of preventing the hair from losing the above effects even when the hair is washed in daily life, and to provide a method for increasing the thickness of the hair.  <P>SOLUTION: The hair treatment agent contains a protein and is used for increasing the hair. The hair treatment agent is composed of two agents comprising a reduction treatment agent containing the protein and an oxidation treatment agent. It is preferable that a content of the protein is 1-70 wt.% based on the reduction treatment agent and the protein comprises a hydrolyzed keratin protein and/or a hydrolyzed silk protein. The method for increasing the thickness of the hair comprised applying the reduction treatment agent containing the protein to the hair and then applying the oxidation treatment agent thereto.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Participants who recently had a stool test that had abnormal results will be asked to participate in this study in order to determine whether the use of a navigator can increase the use of colonoscopy, which is the recommended follow up to an abnormal stool test. A navigator is an individual trained to help patients access necessary health care services and understand the test results and next steps. Participants will be asked to meet the navigator at their colonoscopy appointment and discuss any problems that are experienced in getting the colonoscopy done. This will take about 10 minutes to complete. Participants will tell him or her in their own words how the experience was and whether they faced any barriers to scheduling and colonoscopy completion. Study personnel will also look at participants' electronic medical record to see what testing participants had done that prompted the need for colonoscopy.The study will include about 30 people.
NEW MATERIAL:A human blood platelet-originated cell growth control substance PDGI-alpha. Adsorption characteristics: k not adsorbed on bio-gel P60 in a IN acetic acid aqueous solution and adsorbed on S-sepharose at a pH of 8; stability: 50% of the substance is inactivated by a heating treatment at 100 deg.C for 3 min, 100% of the substance is inactivated with 0.065 M dithioslatol, but the substance is stable in 1N acetic acid; mol.wt. (SDS-polyacrylic amide electrophoresis): exhibits a single band of 26 KD under a non-reducing condition and three bands of 13KD, 8KD and 5 KD under a reducing condition; actions: inhibits the growth of normal animal epithelium tissue cells including rat hepatic cells, accelerates the growth of normal fibroblast cells, but does not exhibit an activity to accelerate the colony formation of NRK-49F cells in a soft agar. USE:A wound-healing drug, immunosuppressant, etc. Since the substance does not exhibit adverse actions such as the concentration of cells, the substance is safe. PREPARATION:For example, a human platelet-originated transforming growth factor, THF-beta is treated with chymotrypsin at 0-2 deg.C for a week.
Outcomes of mesorectal excision patients will be analysed. Medical records will be reviewed and perioperative outcomes retrieved, incl. long-term oncological and functional/quality of life data. A retrospective cohort over 10 years (2007-2016) will serve as a control to a prospective cohort over 10 further years (2017-2026) as to investigate trends in perioperative and oncological outcomes (min. follow-up of 5 years + adequate cohort size). Prospective data on bowel function, urogenital function and quality of life will measured at time of diagnosis and further. Variations in neoadjuvant/adjuvant treatment and surgical approaches will be assessed for their effect on the outcomes of interest.
Surgical revision, potential hospitalization, and extensive post-surgical rehabilitation may be required for the revision and correction of hypertrophic burn scars to restore function and prevent disability. This in turn results in an increased financial burden to the medical system. More importantly, the patient is required to undergo an additional invasive medical procedure that can potentially create further hypertrophic scarring.

Prevention and reduction of hypertrophic scars with non-invasive, cost effective, and evidence based treatment modalities is therefore the most desirable approach. Two of the most generally accepted methods of non-invasive treatment, pressure garments and silicone gel sheeting, have been demonstrated to individually treat hypertrophic scarring. Recently, burn therapists have begun to use silicone bonded material inserts within pressure garments following the logical deduction that the two therapeutic techniques can be combined to resolve many of the cited individual disadvantages, while reaping the benefits of each individual modality. It is the aim of this study to determine the efficacy of these silicone bonded material inserts within pressure garments in the treatment of hypertrophic scarring.
This study aims to explore the effects of climate on the performance and offspring development of aged Merino sheep relocated from an arid, cold environment with harsh grazing conditions to a dry, temperate-cold valley with irrigated pasture production. We utilized time series data from merino sheep in a dry temperate-cold climate in southern Argentina to characterize their growth curves, assess the impact of climate on performance, and compare offspring growth with maternal growth. Our approach involved developing a dynamic model, a non-autonomous differential equation growth curve based on the widely used Brody model. The model considered variables such as local temperature, age, sex, origin, and pregnancy status to determine the optimal combination of parameters for sheep growth in our dataset. The results have shown that moving the old sheep from the steppe to the valley resulted in an increase of an average of 1 kg in weight, but their offspring had an asymptotic weight of 65 kg, 17 kg more than their mothers. The optimum temperature for the growth rate was 15.7+/-0.56 C and 8.7+/-6.3C for the asymptotic weight.
Water is vital to the health of all living organisms. Most animals in captive environments do not consume a sufficient amount water and this commonly results in renal and GI complications. The present invention is related to a beverage composition for promoting hydration of a non-human animal. The beverage composition comprises purified water, such as reverse osmosis water, and an attractant having at least a flavour and an odour. The beverage composition has a unique mimetic property that is appealing to the animal. The beverage composition preferably further comprises one or more biologically active ingredients for promoting GI or renal health, such as an enzyme or a plant extract.